CatalYm appoints CEO amid antibody development

CatalYm GmbH has appointed Scott Clarke as chief executive officer as the company initiates a Phase 2b programme for its lead candidate, visugromab, in non-squamous non-small-cell lung cancer. With over two decades in the biopharma industry, Mr Clarke will oversee from the US both EU and US operations of the Germany-based company. The appointment follows the December 2024 publication in Nature of positive visugromab data and an oversubscribed $150 million Series D financing. Mr Clarke joins CatalYm from Ambagon Therapeutics, where he oversaw its $85 million Series A financing and its discovery pipeline of molecular glues. Previous roles included CEO at Tizona Therapeutics and earlier in his career, leading oncology partnering at Roche.

CatalYm announced the appointment on 9 January 2025.